LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Vitamin B12 Assays Could Be Missing Anemia

By LabMedica International staff writers
Posted on 24 Dec 2012
Print article
A new study suggests that newer competitive-binding luminescence assay (CBLA) tests for measuring cobalamin (vitamin B12) levels may miss more than a third of pernicious anemia cases.

Researchers at Weil Cornell Medical College (New York, NY, USA) wished to examine the sensitivity of CBLA tests for cobalamin. To do so, they used frozen serum samples obtained from 23 untreated pernicious anemia patients (15 with anti-intrinsic factor antibodies and 8 without them). Each patient met five criteria: a low cobalamin level according to a radioisotope-dilution assay, a sufficient volume of the serum used in the radioisotope-dilution assay for additional testing, a clinically expressed cobalamin deficiency, unequivocal proof of pernicious anemia, and a defined anti-intrinsic factor antibody status. Aliquots were tested in three clinical laboratories with the use of different CBLAs.

The results showed that the CBLAs showed false normal values in 6 of 23 (26%), 5 of 23 (22%), and 8 of 23 (35%) serum samples, respectively, as compared with a radioisotope-dilution assay; 5 of the serum samples failed with all three CBLAs. False normal results affected 33%–53% of positive serum samples for anti-intrinsic factor antibodies, but no serum samples that were negative for anti-intrinsic factor antibodies. The activity of anti-intrinsic factor antibodies was nonsignificantly greater in the 9 serum samples with a cobalamin assay error than in the 6 without an error. The study was published on September 6, 2012, as a letter to the editor in the New England Journal of Medicine (NEJM).

“Diagnostic sensitivity of the older microbiologic and radioisotope-dilution assays have been estimated to be about 95%, but since CBLAs have replaced these assays, few studies have compared their sensitivity and specificity with older methods,” concluded study authors Ralph Carmel, MD, and Yash Pal Agrawal, PhD. “The diagnostic failures with all three CBLAs suggest widespread CBLA malfunction. Some speculate that these failures have something to do with the newer tests being unable to inactivate serum anti-intrinsic factor antibodies, which can confound test results.”

Related Links:
Weil Cornell Medical College


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.